Cargando…

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

INTRODUCTION: Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to endocrine therapy by intersecting global gene transcription data from patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribas, Ricardo, Ghazoui, Zara, Gao, Qiong, Pancholi, Sunil, Rani, Aradhana, Dunbier, Anita, Dowsett, Mitch, Martin, Lesley-Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303127/ https://www.ncbi.nlm.nih.gov/pubmed/25358600 http://dx.doi.org/10.1186/s13058-014-0447-1

Ejemplares similares

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
por: Weigel, Marion T, et al.
Publicado: (2012)

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
por: Ribas, Ricardo, et al.
Publicado: (2018)

ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1
por: Dunbier, Anita K., et al.
Publicado: (2011)

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2019)

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2020)

Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer
por: Hazlett, Jody, et al.
Publicado: (2021)

Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016)

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
por: Pancholi, Sunil, et al.
Publicado: (2020)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
por: Simigdala, Nikiana, et al.
Publicado: (2016)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
por: Simigdala, Nikiana, et al.
Publicado: (2018)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
por: Gellert, Pascal, et al.
Publicado: (2016)

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo
por: Martin, Lesley-Ann, et al.
Publicado: (2012)

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
por: Rani, Aradhana, et al.
Publicado: (2019)

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy
por: Haynes, Ben P., et al.
Publicado: (2017)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
por: Richman, Juliet, et al.
Publicado: (2020)

Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.
por: Roberts, M. M., et al.
Publicado: (1978)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Molecular mechanism(s) of endocrine-disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors
por: Lee, Hye-Rim, et al.
Publicado: (2013)

Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer
por: Haynes, Ben P., et al.
Publicado: (2019)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture
por: Fridriksdottir, Agla J., et al.
Publicado: (2015)

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer
por: Gao, Qiong, et al.
Publicado: (2018)

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
por: Haynes, Ben P., et al.
Publicado: (2021)

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
por: Anderson, E. D., et al.
Publicado: (1989)

Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.
por: Leake, R. E., et al.
Publicado: (1981)

Of Oestrogens and Sperm: A Review of the Roles of Oestrogens and Oestrogen Receptors in Male Reproduction
por: Dostalova, Pavla, et al.
Publicado: (2017)

Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)

Oestrogen receptor alpha in pulmonary hypertension
por: Wright, Audrey F., et al.
Publicado: (2015)

Oestrogenic Endocrine Disruptors in the Placenta and the Fetus
por: Tang, Zi-Run, et al.
Publicado: (2020)

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
por: Yeo, B, et al.
Publicado: (2015)

Investigating the functional role of the oestrogen receptor in LY2 endocrine resistant breast cancer cells
por: Ramkaran, Chrisen, et al.
Publicado: (2015)

Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours
por: Skliris, G P, et al.
Publicado: (2006)

Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor.
por: Piva, R., et al.
Publicado: (1990)

Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer
por: Dwyer, Amy R., et al.
Publicado: (2020)

Oestrogen receptor low positive breast cancer: associations with prognosis
por: Skjervold, Anette H., et al.
Publicado: (2023)

Oestrogen and androgen receptors in melanoma.
por: Rümke, P., et al.
Publicado: (1980)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
por: Ellis, Matthew J., et al.
Publicado: (2008)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u1ju8gvqpvkipnpnhjnje5avsq